Overview: Solriamfetol is an orally administered dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist, currently approved by the FDA to improve wakefulness in adult patients with excessive daytime sleepiness related to narcolepsy or obstructive sleep apnea [58]. The gene discussed is TAAR1; the disease is narcolepsy.